Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Loriot

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
Bulletin Du Cancer|June 4, 2010
[Cancer in Africa, a new health challenge. Examples of Mali and OncoMali]M Ly, A Ly, M Rodrigues, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Skeletal-Related Events (SRES) Impact Significantly the Health-Related Quality of Life (HRQOL) of Chemo-Naive Men With Metastatic Castration Resistant Prostate Cancer (MCRPC)C Ivanescu, D Phung, Y Loriot, et al.
British Journal of Cancer|July 15, 2010
BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiationY Loriot, P Mordant, N Dorvault, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2018
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centreF Ruatta, L Derosa, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancerC Serrate, Y Loriot, T De La Motte Rouge, et al.
Prostate Cancer and Prostatic Diseases|October 15, 2014
Who dies from prostate cancer?A Patrikidou, Y Loriot, J-C Eymard, et al.
Bulletin Du Cancer|December 22, 2009
[New drugs in metastatic castration-resistant prostate cancer]L Albiges, Y Loriot, M Gross-Goupil, et al.
BMC Cancer|March 1, 2016
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancerC R Lindsay, S Le Moulec, F Billiot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry StudyC Oing, K Oechsle, A Necchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2009
Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) SurveyY Loriot, L Albiges-Sauvin, D Dionysopoulos, et al.
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Bulletin Du Cancer|June 4, 2010
[Cancer in Africa, a new health challenge. Examples of Mali and OncoMali]M Ly, A Ly, M Rodrigues, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Skeletal-Related Events (SRES) Impact Significantly the Health-Related Quality of Life (HRQOL) of Chemo-Naive Men With Metastatic Castration Resistant Prostate Cancer (MCRPC)C Ivanescu, D Phung, Y Loriot, et al.
British Journal of Cancer|July 15, 2010
BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiationY Loriot, P Mordant, N Dorvault, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2018
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centreF Ruatta, L Derosa, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancerC Serrate, Y Loriot, T De La Motte Rouge, et al.
Prostate Cancer and Prostatic Diseases|October 15, 2014
Who dies from prostate cancer?A Patrikidou, Y Loriot, J-C Eymard, et al.
Bulletin Du Cancer|December 22, 2009
[New drugs in metastatic castration-resistant prostate cancer]L Albiges, Y Loriot, M Gross-Goupil, et al.
BMC Cancer|March 1, 2016
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancerC R Lindsay, S Le Moulec, F Billiot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry StudyC Oing, K Oechsle, A Necchi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 25, 2009
Why do residents choose the medical oncology specialty? Implications for future recruitment--results of the 2007 French Association of Residents in Oncology (AERIO) SurveyY Loriot, L Albiges-Sauvin, D Dionysopoulos, et al.
Pageof 8